84 results about "Induced platelet aggregation" patented technology

The present invention describes a therapeutic method useful for treating or preventing a condition of platelet aggregation in a subject including administering a pharmaceutically effective amount of a compound or composition that inhibits JAK-3 and / or tyrosine phosphorylation of STAT-3 and inhibits thrombin induced platelet aggregation. The condition of platelet aggregation includes hematopoietic and cerbrovascular diseases.

This invention is directed to a method of preventing or treating diseases or conditions associated with platelet aggregation. The method is also directed to a method of treating thrombosis. The method comprises administering to a subject a pharmaceutical composition comprising a therapeutic effective amount of P2Y12 receptor antagonist compound, wherein said amount is effective to bind the P2Y12 receptors on platelets and inhibit ADP-induced platelet aggregation. The P2Y12 receptor antagonist compounds useful for this invention include mononucleoside 5′-monophosphates, mononucleoside polyphosphates, and dinucleoside polyphosphates of general Formula I, or salts thereof. The present invention also provides novel compounds of mononucleoside 5′-monophosphates, mononucleoside polyphosphates, and dinucleoside polyphosphates. The present invention further provides pharmaceutical formulations comprising mononucleoside 5′-monophosphates, mononucleoside polyphosphates, or dinucleoside polyphosphates.

The present invention relates, in general, to a pharmacologic system to modulate the biology of platelets based upon a nucleic acid ligand that can interact with and modulate the activity of platelet glycoprotein GPVI to regulate platelet function. These nucleic acid ligands are also actively reversible using a modulator that inhibits the activity of the nucleic acid ligand to neutralize this pharmacologic effect and thereby restore GPVI function, including collagen binding, platelet adhesion, collagen-induced platelet activation, and collagen-induced platelet aggregation. The invention further relates to compositions comprising the nucleic acid ligand, the ligand and a modulator, methods to generate the nucleic acid ligand and its modulator, as well as methods of using these agents and compositions in medical therapeutic and diagnostic procedures.

The invention discloses caffeic acid diester compounds of formula (I) and prepartion method thereof, and application of preparing medicine for curing thrombus, experments show that the invention synthesized caffeic acid diester compounds has strong inhibition function to platelet aggregation induced by ADP, comparison of 50% aggregation inhibition concentration shows that, the invention provided caffeic acid diester compounds has better inhibition function to platelet aggregation than caffeic acid and acetylsalicylic acid, the caffeic acid diester compounds obtained by condensation of caffeic acid and acetylsalicylic acid has synergistic function with less clinical dosage, reduced untoward effect. The invention provided method for preparing caffeic acid diester compounds uses microwave reaction that reduces reaction time and improves reaction efficiency, and the cost is reduced, the invention also has excellent operability and certain protection function to environment.

Disclosed herein are recombinant proteins capable of inducing platelet aggregation and uses thereof.

The invention discloses an anti-platelet-aggregation polypeptide, belongs to the field of medical biotechnology, and in particular relates to a novel polypeptide having the function of inhibiting platelet aggregation. The polypeptide is a polypeptide KM6 consisting of 10 amino acids, having a sequence of SEQ ID NO: 1, and having a molecular weight of 1103. 19 Da, and the sequence of the polypeptide KM6 is Gln-Leu-Ser-Asn-Gly-Asn-Arg-Thr-Leu-Thr. The polypeptide has obvious inhibitory effects on collagen, ADP, arachidonic acid and thrombin-induced platelet aggregation, can be used for exploringthe influence of the polypeptide KM6 and other platelet activators (such as epinephrine and ristomycin) on the effect and related functions of platelets, and can also be used to monitor existing antiplatelet therapies.

The invention relates to C27 spirostane-type steroidal saponins isolated from Ypsilandra, Trillium and Paris and their preparation method, as well as their application in the preparation of drugs for treating hemorrhagic diseases, and application in the preparation of drugs for treating dysfunctional uterine bleeding, and the preparation of functional daily chemical products and health products. The materials used in a method of the invention are easy to obtain, the method is simple and easily operable, biological experiments of the compound produced show that the compound can induce platelet aggregation activity and hemostatic activity significantly.

The invention discloses an anti-platelet aggregation polypeptide 6X. The polypeptide is the polypeptide 6X composed of 10 amino acids, has a sequence of SEQ ID NO:1, and has the molecular weight of 1103.19 Da; the sequence is Thr-Asn-Leu-Thr-Ser-Arg-Asn-Leu-Gly-Gln; the polypeptide is not limited to inhibition of platelet aggregation induced by an Fc[gamma]RIIA specific activator anti-CD9; and thepolypeptide can be used for exploring the influence of the polypeptide and other platelet activators (collagen, arachidonic acid, ADP, epinephrine, ristomycin and the like) on the effects and relatedfunctions of platelets, and can also be used for monitoring existing antiplatelet treatment.

The invention discloses a ligustrazine derivative and a preparation method and medical application thereof. The invention synthesizes and prepares three ligustrazine derivatives with novel structures,and provides a preparation method of the ligustrazine derivatives. Pharmacological results show that the inhibitory activity of the three ligustrazine derivatives I-2, I-4 and I-6 on ADP-induced or AA-induced platelet aggregation is superior to that of a parent compound ligustrazine (TMP); compared with clinically common medicines with anticoagulant effects, the activity of the ligustrazine derivatives I-2, I-4 and I-6 in inhibition of ADP-induced platelet aggregation is equivalent to that of a positive drug thilopyrazine, and the inhibition activity of the ligustrazine derivatives I-2, I-4 and I-6 in inhibition of AA-induced platelet aggregation is obviously superior to that of a positive control drug aspirin.

The invention discloses a ligustrazine-butyphthalide combination compound, a preparation method of the ligustrazine-butyphthalide combination compound and an application of the ligustrazine-butyphthalide combination compound to pharmaceuticals. The ligustrazine-butyphthalide combination compound has the following structural formula I as in the description. The phthalic anhydride and the ligustrazine are taken as starting materials, bromization, nucleophilic addition, catalytic dehydration, ester hydrolysis, reduction and esterification reactions are conduced to prepare the ligustrazine-butyphthalide combination compound; a pharmaceutical composition takes the ligustrazine-butyphthalide combination compound as an active pharmaceutical ingredient and is a pharmaceutically acceptable carrier, excipient, diluent, adjuvant, intermedium or a composition. The prepared ligustrazine-butyphthalide combination compound has an excellent effect of inhibiting in-vitro platelet aggregation (ADP) induced platelet aggregation, has a better in-vivo pharmacokinetics properties, and can be used for preventing and treating cardiovascular and cerebrovascular diseases, vascular senile dementia and the complications.

The invention provides an antithrombotic medicament for intravenous injection. The medicament is a modified acidic polysaccharide consisting of only one monosaccharide and has a structural general formula, wherein R is -CH3 or -CH2-CH(OH)-CH3; R' is -H or -SO3Na; each sugar ring has at least one R' which is -SO3Na; n is equal to 2 to 6; when R is -CH3, the compound represented by the structural general formula is an oligomannuronicacid methyl acetate sulfate sodium salt; and when R is -CH2-CH(OH)-CH3, the compound represented by the structural general formula is an oligomannuronicacid proply acetate sulfate sodium salt. The medicament for intravenous injection has obvious anticoagulation, wherein the anticoagulation titer is 17 to 23; rabbit collagen induced platelet aggregation and platelet adhesion are obviously inhibited; and local ischemic brain damage caused by formation of cerebral thrombosis is lessened by inhibiting the formation of cerebral thrombosis and ischemic brain tissues are obviously protected.

The present invention is related to heparin-like compounds characterized by their capacity of inhibiting collagen-induced platelet aggregation in flowing whole blood and their use for prophylactic treatment of arterial thrombosis associated with vascular or microvascular injury and interventions. Said properties are related to a high coupling density of negatively charged heparin or heparin-like glycosaminoglycan molecules, present in multiple heparin or heparin-like glycosaminoglycans as well as in proteoglycans containing said multiple heparin or heparin-like glycosaminoglycans or lower-molecular-weight heparin or heparin-like glycosaminoglycans connected directly or through spacer / linker molecules to globular core molecules. Heparin-like compounds, with said properties are obtainable from mammalian mast cells, by tissue extraction or cell cultivation. The heparin-like compounds of the present invention can also be produced by synthetical, semisynthetical and / or biotechnological methods and they are useful for manufacturing preparations, means and devices for local or topical application in prophylactic treatment of arterial thrombosis and its sequelae.

The invention discloses polypeptide PEP1 promoting platelet aggregation, belongs to the field of medical biotechnology, and in particular relates to a novel polypeptide having the function of promoting platelet aggregation. The polypeptide PEP1 is a polypeptide consisting of 14 amino acids, having a sequence of SEQ ID NO: 1, and having a molecular weight of 1564.77Da, and the sequence of the polypeptide PEP1 is Thr-Ile-Tyr Pro-Asn-Ala-Ser-Leu-Leu-Ile-Gln-Asn-Val-Thr. The polypeptide has a significant promoting effect on thrombin-induced platelet aggregation, can be used to explore the influence of the polypeptide PEP1 and other platelet activators on the effect and related functions of platelets, can also be used to monitor existing antiplatelet therapy, and can be applied to preparation of drugs for promoting platelet aggregation, stopping bleeding and treating cardiovascular diseases.

The invention discloses an oligopeptide containing an Hyp-Gly sequence and having antiplatelet and antithrombotic functions. The invention provides the oligopeptide containing the Hyp-Gly sequence orsalt forms thereof. The oligopeptide containing an OG sequence can be prepared through artificial synthesis as well as enzymolysis of fish skin. The molecular weight of the oligopeptide containing theOG sequence is smaller than 1,000 Da, the mass ratio of the oligopeptide to total enzyme-digested products is 65%-95%, and the oligopeptide has a specific inhibition effect on ADP-induced platelet aggregation, can inhibit thrombosis, does not affect the blood coagulation function, does not prolong the bleeding time and is very small in bleeding risk; and the oligopeptide has the characteristics of resistance to gastrointestinal tract digestive enzyme enzymolysis and easiness in absorption.

The invention discloses polypeptide 8496 promoting platelet aggregation, belongs to the field of medical biotechnology, and particularly relates to a polypeptide having a function of promoting the platelet aggregation. The preparation is the polypeptide 8496 having thrombin-induced human platelet aggregation, the sequence is Ile-Gly-Thr-Gln-Gln-Ala-Thr-Pro-Gly-Pro-Ala-Asn-Ser, the substance of thesynthesized polypeptide is a complete amino acid sequence. The polypeptide has a significant promoting effect on collagen-induced platelet aggregation, can be used for developing a new generation ofclinically-effective platelet aggregation promoting and hemostatic drugs, and can be used for exploring the influence of the polypeptide 8496 and other platelet activators on the effect and related functions of platelets.

The invention provides an oligopeptide R-G-S(p)-L-P capable of influencing platelet function or trim / derivate thereof and application of the oligopeptide R-G-S(p)-L-P or trim / derivate thereof in preventing and / or treating arterial thrombus disease and / or related disease interacted by platelet GPIbalpha and ABP. The platelet treated by the oligopeptide R-G-S(p)-L-P or trim / derivate thereof can effectively inhibit adhesion function of the platelet including ristomycin induced platelet aggregation function without influencing platelet aggregation function including ADP induced platelet aggregation function, thus inhibiting thrombopoiesis while basically maintaining the integrity of platelet functional status. The invention can be directly used for research and development of clinical anti-thrombus medicine.

The present invention relates, in general, to a pharmacologic system to modulate the biology of platelets based upon a nucleic acid ligand that can interact with and modulate the activity of platelet glycoprotein GPVI to regulate platelet function. These nucleic acid ligands are also actively reversible using a modulator that inhibits the activity of the nucleic acid ligand to neutralize this pharmacologic effect and thereby restore GPVI function, including collagen binding, platelet adhesion, collagen-induced platelet activation, and collagen-induced platelet aggregation. The invention further relates to compositions comprising the nucleic acid ligand, the ligand and a modulator, methods to generate the nucleic acid ligand and its modulator, as well as methods of using these agents and compositions in medical therapeutic and diagnostic procedures.

The invention discloses a traditional Chinese medicine recipe for treating rheumatoid arthritis, which relates to the field of traditional Chinese medicine preparations. The traditional Chinese medicine recipe for treating the rheumatoid arthritis is characterized by comprising sixteen traditional Chinese medicines: Angelica sinensis, Radix rehmanniae Preparata, Ligusticum wallichii, radix paeoniae alba, radices sileris, notopterygium root, frankincense, myrrh, Monkshood, dried tangerine or orange peel, cassia twig, liquorice, Caulis Spatholobi, Radix Salviae Miltiorrhizae, Rhizoma Gastrodiae and Pangolin Scales. The sixteen traditional Chinese medicines are taken three times a day after being soaked in white wine for 7 days. The invention has the beneficial effects that the traditional Chinese medicine recipe for treating the rheumatoid arthritis is capable of effectively promoting blood circulation and removing blood stasis, freeing channels and stopping pains and improving the symptom of blood stasis. The whole blood viscosity and the plasma viscosity are reduced, red blood cell aggregations are reduced, and the plasma proteins are reduced; an obvious inhibitory action is performed on adenosine diphosphate (ADP)-induced platelet aggregations, agglomerate platelets can be rapidly depolymerized, and the red blood cell aggregations in microcirculation are delayed and relieved, thereby, the blood viscosity is reduced, the blood agglomeration state is improved, blood vessels are dilated, smooth muscle spasm is relieved and the pains are relieved. The traditional Chinese medicine recipe disclosed by the invention is a pure traditional Chinese medicine preparation, does not have toxic and side effects and has an obvious effect.

The invention belongs to the field of pharmaceuticals, and particularly relates to an application of NADPH (triphosphopyridine nucleotide) in preparation of antiplatelet aggregation drugs. The research shows that in-vitro delivery of exogenous NADPH inhibits ADP (adenosine diphosphate) induced platelet aggregation of rats in a dose-dependent mode; in-vitro delivery of exogenous NADPH inhibits Thrombin induced platelet aggregation of the rats in a dose-dependent mode; preventive delivery of NADPH in the rats can remarkably inhibit ADP induced platelet aggregation; preventive delivery of NADPH in the rats can remarkably inhibit Thrombin induced platelet aggregation. Therefore, NADPH has the antiplatelet aggregation function and can be taken as a potential antiplatelet aggregation drug.

The present invention relates to a novel compound having an effect of inhibiting platelet aggregation and a salt thereof and, more specifically, to: a novel platelet aggregation inhibitor specifically inhibiting shear stress-induced platelet aggregation; a pharmaceutical composition containing the same as an active ingredient; and a preparation method therefor.

The present invention relates, in general, to a pharmacologic system to modulate the biology of platelets based upon a nucleic acid ligand that can interact with and modulate the activity of platelet glycoprotein GPVI to regulate platelet function. These nucleic acid ligands are also actively reversible using a modulator that inhibits the activity of the nucleic acid ligand to neutralize this pharmacologic effect and thereby restore GPVI function, including collagen binding, platelet adhesion, collagen-induced platelet activation, and collagen-induced platelet aggregation. The invention further relates to compositions comprising the nucleic acid ligand, the ligand and a modulator, methods to generate the nucleic acid ligand and its modulator, as well as methods of using these agents and compositions in medical therapeutic and diagnostic procedures.

The invention provides an anti-platelet aggregation pharmaceutical composition comprising cinnamic acid, p-coumaric acid and coumarin, wherein the molar concentration ratio of the cinnamic acid to the p-coumaric acid to the coumarin is (1-9):(1-9):(4-36). The experiment result shows that the inhibiting effect on ADP-induced platelet aggregation caused by combined utilization of the cinnamic acid, the p-coumaric acid and the coumarin is obviously higher than that caused by independent use of the coumarin.

Disclosed are 5-nitrobenzoate derivatives of Formula I,and the preparation method therefor, wherein R is referred to hydrogen (H), unsubstituted, mono-substituted, di-substituted or tri-substituted benzoyl moiety. 5-Nitrobenzoate derivatives of Formula I do not affect the platelet aggregation, possesses the inhibitory activity related to the tumor cell-induced platelet aggregation (TCIPA), and further specifically inhibits podoplanin-induced platelet aggregation. Therefore, 5-nitrobenzoates of the invention are applicable in its therapeutic use as the novel therapeutic agent in preventing tumor metastasis.

The present invention relates, in general, to a pharmacologic system to modulate the biology of platelets based upon a nucleic acid ligand that can interact with and modulate the activity of platelet glycoprotein GPVI to regulate platelet function. These nucleic acid ligands are also actively reversible using a modulator that inhibits the activity of the nucleic acid ligand to neutralize this pharmacologic effect and thereby restore GPVI function, including collagen binding, platelet adhesion, collagen-induced platelet activation, and collagen-induced platelet aggregation. The invention further relates to compositions comprising the nucleic acid ligand, the ligand and a modulator, methods to generate the nucleic acid ligand and its modulator, as well as methods of using these agents and compositions in medical therapeutic and diagnostic procedures.

The invention discloses a platelet aggregation resistant aloe extract and an application thereof in PRP preparation. The application comprises steps as follows: preparation of an aloe extract; ADP induced platelet aggregation resistance detection and PRP preparation and activation. The aloe extract has a remarkable inhibition function on ADP induced platelet aggregation, the aloe extract and sodium citrate are combined to be used as anticoagulants, prepared PRP has higher concentration and activity, and the PRP can be used to related clinical applications such as wound repair and the like after activation.